S&P 500   0.57 (+2.14%)
DOW   0.57 (+2.14%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   0.57 (+2.14%)
DOW   0.57 (+2.14%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   0.57 (+2.14%)
DOW   0.57 (+2.14%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   0.57 (+2.14%)
DOW   0.57 (+2.14%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
Log in

NASDAQ:BIIBBiogen Price Target & Analyst Ratings

$300.26
-5.45 (-1.78 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$298.42
Now: $300.26
$308.50
50-Day Range
$258.66
MA: $275.33
$305.71
52-Week Range
$215.77
Now: $300.26
$374.99
Volume1.52 million shs
Average Volume1.84 million shs
Market Capitalization$47.54 billion
P/E Ratio8.79
Dividend YieldN/A
Beta0.56

Analyst Ratings

Biogen (NASDAQ:BIIB) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
31 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $312.79, suggesting that the stock has a possible upside of 4.17%. The high price target for BIIB is $410.00 and the low price target for BIIB is $228.00. There are currently 4 sell ratings, 16 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.232.132.202.21
Ratings Breakdown: 4 Sell Rating(s)
16 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
17 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
14 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
20 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $312.79$309.63$317.46$312.96
Price Target Upside: 4.17% upside11.70% upside8.28% upside7.66% downside

Biogen (NASDAQ:BIIB) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen (NASDAQ:BIIB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/7/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$270.00 ➝ $375.00Medium
8/7/2020OppenheimerBoost Price TargetOutperform$325.00 ➝ $360.00High
7/31/2020Raymond JamesReiterated RatingSellLow
7/29/2020JPMorgan Chase & Co.Reiterated RatingHold$279.00Low
7/27/2020Morgan StanleyUpgradeUnderweight ➝ Overweight$263.00 ➝ $357.00High
7/23/2020BMO Capital MarketsLower Price TargetMarket Perform$317.00 ➝ $280.00Low
7/22/2020MizuhoReiterated RatingHold$316.00Low
7/22/2020Wells Fargo & CoBoost Price TargetEqual Weight$311.00 ➝ $324.00Low
7/22/2020Stifel NicolausLower Price TargetPositive ➝ Hold$294.00 ➝ $284.00Medium
7/13/2020Goldman Sachs GroupLower Price TargetNeutral$300.00 ➝ $257.00Medium
7/10/2020William BlairReiterated RatingHoldLow
7/8/2020SunTrust BanksReiterated RatingBuy$330.00Low
7/8/2020GuggenheimReiterated RatingBuy$390.00Low
7/6/2020Royal Bank of CanadaReiterated RatingHold$276.00Low
6/22/2020BarclaysDowngradeOverweight ➝ Equal Weight$370.00 ➝ $280.00Low
6/19/2020Robert W. BairdLower Price TargetUnderperform$290.00 ➝ $228.00High
6/19/2020Piper SandlerLower Price TargetNeutral$307.00 ➝ $260.00High
6/9/2020Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$360.00 ➝ $297.00Medium
5/1/2020Cantor FitzgeraldReiterated RatingNeutral$361.00 ➝ $308.00Low
4/24/2020Canaccord GenuityLower Price TargetBuy$360.00 ➝ $350.00Medium
4/23/2020CitigroupDowngradeNeutral ➝ Sell$365.00 ➝ $240.00Low
4/22/2020WedbushLower Price TargetNeutral$306.00 ➝ $295.00High
4/8/2020SVB LeerinkReiterated RatingOutperformHigh
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$331.00Low
2/7/2020Nomura SecuritiesBoost Price TargetBuy$320.00 ➝ $392.00Low
2/6/2020HC WainwrightReiterated RatingBuy$335.00Medium
1/2/2020CowenReiterated RatingBuy$325.00Low
11/1/2019Standpoint ResearchDowngradeBuy ➝ HoldLow
10/23/2019Bank of AmericaBoost Price TargetUnderperform$200.00 ➝ $235.00Low
10/22/2019Jefferies Financial GroupBoost Price TargetHold$255.00 ➝ $310.00High
10/22/2019UBS GroupBoost Price TargetOutperform ➝ Positive$280.00 ➝ $334.00High
7/26/2019Piper Jaffray CompaniesReiterated RatingHoldN/A
5/7/2019ArgusReiterated RatingHoldHigh
3/21/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
3/21/2019Atlantic SecuritiesDowngradeOverweight ➝ NeutralHigh
1/26/2018Deutsche BankReiterated RatingBuy$373.00Low
(Data available from 8/10/2018 forward)
This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.